Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme
Creators
- 1. Medical University Innsbruck, Department for Psychiatry and Psychotherapy, Innsbruck (Austria)
- 2. Medical University Innsbruck, Department for Nuclear Medicine, Innsbruck (Austria)
- 3. University of Mainz, Institute of Medical Biostatistics, Epidemiology, and Informatics, Mainz (Germany)
- 4. Netherlands Cancer Institute, Amsterdam (Netherlands)
Description
Health-related quality of life (HRQOL) in differentiated thyroid cancer (DTC) research has so far received little attention and available results are conflicting. We studied the HRQOL of radioiodine-naive DTC patients in comparison with the general population (GP), investigated the course of HRQOL up to 30 months after radioiodine remnant ablation (RAA) and sought to identify patient characteristics associated with HRQOL. We analysed data from routine HRQOL monitoring at a nuclear medicine department. Between 2005 and 2013, a total of 439 thyroid cancer patients (all histologies) completed the EORTC Quality of Life Questionnaire Core-30 (QLQ-C30) at least once during their treatment at the department. We compared patients' baseline HRQOL scores before RAA with scores from age-matched and sex-matched controls from the Austrian GP. We then determined the course of HRQOL over the 30 months after RAA and assessed the impact of the following clinical variables on HRQOL: method of thyroid-stimulating hormone (TSH) stimulation, histology (papillary vs. follicular) and disease stage. A total of 284 patients (mean age 48.3 years, SD 15.0 years; 71.6 % women; 80.7 % papillary type) with a baseline HRQOL assessment before RAA were available. We found clinically meaningful differences in the detriment in patients on almost all domains. These were largest for fatigue (23 points) and role functioning (25 points). Data from 241 patients (mean age 48.6 years, SD 15.9 years; 68.9 % women; 76.3 % papillary type) were included in the longitudinal analysis. Investigating the course of HRQOL, a significant improvement over time was found for role and emotional functioning, fatigue, pain, and dyspnoea. A range of HRQOL scores were improved in patients with exogenous TSH stimulation, but some scores both in patients with exogenous TSH stimulation and in those followed for 30 months, especially fatigue and role functioning, did not reach levels in the GP sample. Our results show that the favourable prognosis of DTC does not directly translate into good HRQOL in these patients. Persistent restrictions in regaining their normal daily life in terms of work and leisure highlight the importance of more detailed investigation of DTC patients' wellbeing, support needs, and disease experience. (orig.)
Availability note (English)
Available from: http://dx.doi.org/10.1007/s00259-015-3022-9Additional details
Identifiers
Publishing Information
- Journal Title
- European Journal of Nuclear Medicine and Molecular Imaging
- Journal Volume
- 42
- Journal Issue
- 8
- Journal Page Range
- p. 1179-1188
- ISSN
- 1619-7070
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 46092883
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ABLATION; AGE DEPENDENCE; BIOLOGICAL FATIGUE; BIOLOGICAL RADIATION EFFECTS; CARCINOMAS; HEALTH HAZARDS; HUMAN FACTORS; IODINE 131; MONITORING; RADIATION DOSES; RADIOTHERAPY; SEX DEPENDENCE; SIDE EFFECTS; SOCIAL IMPACT; STANDARD OF LIVING; THYROID; THYROIDECTOMY
- Descriptors DEC
- BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; BIOLOGICAL EFFECTS; BODY; DAYS LIVING RADIOISOTOPES; DISEASES; DOSES; ENDOCRINE GLANDS; GLANDS; HAZARDS; INTERMEDIATE MASS NUCLEI; IODINE ISOTOPES; ISOTOPES; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; NUCLEI; ODD-EVEN NUCLEI; ORGANS; RADIATION EFFECTS; RADIOISOTOPES; RADIOLOGY; SURGERY; THERAPY